Enliven Therapeutics, Inc. reports that Vestal Point Capital and Ryan Wilder beneficially own 3,250,000 shares of Common Stock, representing 5.4% of the class. The percentage is calculated using 59,800,406 shares outstanding as of February 19, 2026, per the company's referenced annual report. The filing states the shares are held by the Vestal Point Fund and Account and that the Reporting Persons have shared voting and dispositive power over these shares. The amendment is signed by Ryan Wilder on 05/15/2026.
Positive
None.
Negative
None.
Insights
Vestal Point holds a 5.4% stake via shared control of 3,250,000 shares.
The filing is an amended Schedule 13G/A reporting that the Vestal Point Fund and Account directly hold 3,250,000 shares and that voting and dispositive power is shared. The percentage basis is an aggregate of 59,800,406 shares outstanding as of February 19, 2026.
Ownership is reported as held on behalf of the Vestal Point Fund and Account per Item 6. Subsequent filings or company disclosures would show any changes; timing and cash‑flow treatment are not described in this excerpt.
Amendment clarifies attribution and power; signature by the managing partner is included.
The statement identifies the Investment Manager (Vestal Point Capital, LP) and Ryan Wilder as Reporting Persons and expressly notes the filing should not be construed as an admission of beneficial ownership for Section 13 purposes. Signatures show both entity and individual attestations dated 05/15/2026.
Practically, this is a statutory disclosure of passive/beneficial ownership and control attributes; any change above the 5% threshold would trigger further reporting obligations.
Key Figures
Shares beneficially owned:3,250,000 sharesPercent of class:5.4%Shares outstanding (basis):59,800,406 shares+1 more
4 metrics
Shares beneficially owned3,250,000 sharesReported for Vestal Point Fund and Account
Percent of class5.4%Calculated using outstanding shares as of February 19, 2026
Shares outstanding (basis)59,800,406 sharesOutstanding as of February 19, 2026 (per referenced annual report)
Filing signature date05/15/2026Signed by Ryan Wilder for the reporting persons
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared dispositive powerregulatory
"Shared Dispositive Power 3,250,000.00"
Schedule 13G/Aregulatory
"This statement is filed by: Vestal Point Capital, LP ..."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
What stake does Vestal Point Capital hold in Enliven Therapeutics (ELVN)?
Vestal Point Capital and Ryan Wilder report 3,250,000 shares, representing 5.4% of Enliven Therapeutics' Common Stock based on 59,800,406 shares outstanding as of February 19, 2026.
Who is reported as the beneficial owner on this Schedule 13G/A for ELVN?
The filing lists Vestal Point Capital, LP (the Investment Manager) and Ryan Wilder as Reporting Persons, with the Vestal Point Fund and Account holding the reported Common Stock directly.
Does the filing state voting or dispositive power for the reported shares?
Yes. The filing shows the Reporting Persons have shared voting power and shared dispositive power over the 3,250,000 shares reported on the cover page.
What date and document establish the outstanding share base used in the percentage calculation?
The percentage uses 59,800,406 shares outstanding as of February 19, 2026, referenced from the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2026, filed March 3, 2026.
Was the Schedule 13G/A signed and when?
The amendment is signed by Ryan Wilder for both Vestal Point Capital, LLC (as general partner) and individually, with the signature date shown as 05/15/2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Enliven Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
29337E102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Vestal Point Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,250,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,250,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,250,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
29337E102
1
Names of Reporting Persons
Ryan Wilder
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,250,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,250,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,250,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Enliven Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6200 Lookout Road, Boulder, Colorado 80301
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of Enliven Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and
(ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)
Citizenship:
The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
29337E102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 59,800,406 shares of Common Stock outstanding as of February 19, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2026, filed with the Securities and Exchange Commission on March 3, 2026.
(b)
Percent of class:
5.4%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vestal Point Capital, LP
Signature:
/s/ Ryan Wilder
Name/Title:
By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
